KRAS and cancer: Puzzled by the negative results of the CANOPY-2 trial, we focused on published mutation data from incident LUAD from the CANTOS trial [49] and cross-examined them with the cancer genome atlas (TCGA) LUAD dataset [50], hypothesizing that IL-1β neutralization with canakinumab would specifically prevent the development of incipient KRAS-mutant (MUT) LUAD.